Swiss drugmaker Novartis buys Takeda's dry eye drug for US$3.4b
Add BT as a preferred source
DeeperDive is a beta AI feature. Refer to full articles for the facts.
[BENGALURU] Swiss drugmaker Novartis AG said on Wednesday it agreed to acquire Japan-headquartered Takeda Pharmaceutical Company's dry eye drug Xiidra for an upfront payment of US$3.4 billion to expand its portfolio of eye care medicines.
The deal includes potential milestone payments of up to US$1.9 billion and is expected to close in the second half of 2019.
REUTERS
Share with us your feedback on BT's products and services
TRENDING NOW
Autobahn Rent A Car directors declared bankrupt over S$50 million each owed to DBS
Amazon’s MGM Studios gains creative control over ‘James Bond’ franchise
UOB’s Wee Ee Cheong says S$4.9 billion Citi deal ‘paying off’ as Asean push accelerates
In taxing wealth, how far can Singapore push property owners?
